Disc colours in field and cluster spiral galaxies at 0.5 ≲z≲ 0.8

We present a detailed study of the colours of late-type galaxy discs for ten of the EDisCS galaxy clusters with 0.5 ≲ z ≲ 0.8. Our cluster sample contains 172 spiral galaxies, and our control sample is composed of 96 field disc galaxies. We deconvolved their ground-based V and I images obtained with FORS2 at the VLT with initial spatial resolutions between 0.4 and 0.8 arcsec to achieve a final resolution of 0.1 arcsec with 0.05 arcsec pixels, which is close to the resolution of the ACS at the HST. After removing the central region of each galaxy to avoid pollution by the bulges, we measured the V−I colours of the discs. We find that 50% of cluster spiral galaxies have disc V−I colours redder by more than 1σ of the mean colours of their field counterparts. This is well above the 16% expected for a normal distribution centred on the field disc properties. The prominence of galaxies with red discs depends neither on the mass of their parent cluster nor on the distance of the galaxies to the cluster cores. Passive spiral galaxies constitute 20% of our sample. These systems are not abnormally dusty. They are are made of old stars and are located on the cluster red sequences. Another 24% of our sample is composed of galaxies that are still active and star forming, but less so than galaxies with similar morphologies in the field. These galaxies are naturally located in the blue sequence of their parent cluster colour–magnitude diagrams. The reddest of the discs in clusters must have stopped forming stars more than ~5 Gyr ago. Some of them are found among infalling galaxies, suggesting preprocessing. Our results confirm that galaxies are able to continue forming stars for some significant period of time after being accreted into clusters, and suggest that star formation can decline on seemingly long (1 to 5 Gyr) timescales

DIFFUSE JUVENILE SYSTEMIC SCLEROSIS PATIENTS SHOW DISTINCT ORGAN INVOLVEMENT, ANTIBODY PATTERN AND HAVE SIGNIFICANTLY MORE SEVERE DISEASE IN THE LARGEST JSSC COHORT OF THE WORLD. RESULTS FROM THE JUVENILE SCLERODERMA INCEPTION COHORT

Peer reviewe

2018 Research & Innovation Day Program

A one day showcase of applied research, social innovation, scholarship projects and activities.https://first.fanshawec.ca/cri_cripublications/1005/thumbnail.jp

Antidiabetic Molecule Efficacy in Patients with Type 2 Diabetes Mellitus—A Real-Life Clinical Practice Study

In this paper, we aim to evaluate the efficacy of antidiabetic cardioprotective molecules such as Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) and Glucagon-like Peptide 1 Receptor Agonists (GLP-1 RAs) when used with other glucose-lowering drugs, lipid-lowering, and blood pressure (BP)-lowering drugs in a real-life setting. A retrospective, observational study on 477 patients admitted consecutively in 2019 to the outpatient clinic of a tertiary care unit for Diabetes Mellitus was conducted. Body mass index (BMI), blood pressure (BP) (both systolic and diastolic), and metabolic parameters, as well as A1c hemoglobin, fasting glycaemia and lipid profile, including total cholesterol (C), HDL-C, LDL-C and triglycerides), were evaluated at baseline and two follow-up visits were scheduled (6 months and 12 months) in order to assess the antidiabetic medication efficacy. Both SGLT-2i and GLP-1 RAs were efficient in terms of weight control reflected by BMI; metabolic control suggested by fasting glycaemia and A1c; and the diastolic component of BP control when comparing the data from the 6 and 12-month visits to the baseline, and when comparing the 12-month visit to the 6-month visit. Moreover, when comparing SGLT-2i and GLP-1 RAs with metformin, there are efficacy data for SGLT-2i at baseline in terms of BMI, fasting glycaemia, and HbA1c. In this retrospective study, both classes of cardioprotective molecules, when used in conjunction with other glucose-lowering, antihypertensive, and lipid-lowering medications, appeared to be efficient in a real-life setting for the management of T2DM